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Methicillin-resistant Staphylococcus aureus (MRSA) organisms continue
to evolve to circumvent antibiotics. Between 9% and 24% of patients in in-
tensive care units are colonized with MRSA [1]. In addition, S aureus was
responsible for 20% of all bloodstream infections in 24,179 patients in a na-
tionwide surveillance study with an incidence of 10.3 bloodstream infections
per 10,000 patient admissions [2]. Of these S aureus isolates, 41% were clas-
sified as MRSA over the 7-year study period. Alarmingly, methicillin resis-
tance increased from 22% in 1995 to 57% in 2001 (P!.001). In a separate
study, S aureus accounted for 31% to 47% of ventilator-associated pneumo-
nias (VAPs), with MRSA responsible for 11.8% to 18.3% of nosocomial
pneumonias [3].
Some studies also suggest that infection with MRSA is associated with
increased morbidity as compared with that of methicillin-sensitive S aureus
(MSSA) infections. In a study of bacteremia, infection with MRSA was an
independent predictor of mortality (odds ratio, 1.47; 95% CI, 0.99–2.26) [4].
In a multivariate analysis, this effect was independent of age, date of admis-
sion, previous isolation of MRSA, or specialty of care. The increase in mor-
tality may be due to increased virulence of MRSA, suboptimal treatment
options, or increased severity of illness in MRSA-infected patients.
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250 TVERDEK et alVancomycin has long been the mainstay treatment for MRSA infection,
but this practice has recently come under scrutiny. Not only are there strains
that are frankly resistant to vancomycin, but there also appears to be an in-
creased incidence of vancomycin-intermediate S aureus (VISA) [5,6]. There
is also a concern of heteroresistant VISA. Such organismsmay appear initially
susceptible to vancomycin, but treatment with vancomycin appears to select
a VISA subpopulation and clinical failure can occur [7,8]. Furthermore there
is a phenomenon that has been labeled vancomycin ‘‘minimum inhibitory con-
centration creep’’ (‘‘MIC creep’’) [9]. S aureus is defined as vancomycin sus-
ceptible when the vancomycin MIC is 4 mg/mL or less [10]. In recent years,
there have been several reports of MRSA isolates with vancomycin MICs of
1 or 2 mg/mL. In a recent study of 662 MRSA isolates over a 5-year period
[9], the geometric mean MIC increased from 0.62 mg/mL (range, 0.25–1 mg/
mL) to 0.94 mg/mL (range, 0.5–2 mg/mL) (P!.0001). The MIC increase is
of concern because poorer outcomes have been associated with higher vanco-
mycin MICs [11,12]. Sakoulas and colleagues [11] performed a retrospective
subgroup analysis of patients enrolled in a prospective study examining the
treatment of MRSA bacteremia. Success with vancomycin was associated
with vancomycin MIC levels of less than or equal to 0.5 mg/mL (55.6% cure
rate) versus those with vancomycin MIC levels of 1 to 2 mg/mL (9.5% cure
rate) (P ¼ .02). In addition, vancomycin bactericidal activity was determined
for each isolate. Bactericidal activity of vancomycin appeared to correlate
with treatment outcome. No cure took place in any patient whose isolates
had a log10 (colony forming units CFU) per milliliter [CFU/mL]) killing at
72 hours of less than 4.71, while nine isolates with a log10 CFU/mL of 6.27
or greater had a 50% treatment success rate (P ¼ .0027). In a multivariate
analysis, bactericidal activity and MIC were predictive of treatment failure
(odds ratio, 10.73; 95% CI, 1.24–92.95; P ¼ .031, and odds ratio, 35.46;
95%CI, 1.76–715.95;P¼ .02, respectively). Hidayat and colleagues [13] eval-
uated 95 patients with infection caused by MRSA treated with vancomycin
targeted to attain trough levels (free drug) four to five times the vancomycin
MIC. Patients were stratified by MIC of the offending MRSA pathogen.
Fifty-four percent of patients were in the ‘‘high MIC’’ group, defined as van-
comycin MIC greater than or equal to 2 mg/mL, and 46% of patients were in
the ‘‘lowMIC’’ groupwith a vancomycinMIC less than 2 mg/mL. Baseline de-
mographic characteristicswerewellmatched. In the analysis, treatment failure
was associated with increased age (P ¼ .006), Acute Physiology and Chronic
Health Enquiry II (APACHE II) score (P!.001), andMIC greater than 2 mg/
mL (P ¼ .01). MIC greater than or equal to 2 mg/mL was associated with an
increased risk of failure, despite attaining the pharmacodynamic goal of an
unbound vancomycin trough of four to five times the MIC.
Finally, in a study by Moise and colleagues [12] to determine predictors
of prolonged bacteremia during treatment with vancomycin, 34 patients
with MRSA bacteremia were studied. Vancomycin was dosed to achieve tar-
get peak serum levels of 28 to 32 mg/mL and trough levels of 8 to 12 mg/mL.
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or osteomyelitis were excluded. There were 13 MRSA isolates with a vanco-
mycin MIC of 0.5 mg/mL, 7 with an MIC of 1 mg/mL, and 14 with an MIC
of 2 mg/mL. Multiple phenotypic variables were examined. These included
agr group (type II or non–type II), delta-hemolysin expression, vancomycin
MIC for each clinical isolate, bactericidal activity 16 mg/mL of vancomycin
at 24 hours in an inoculum of 107 to 108 CFU/mL of each clinical isolate,
and baseline characteristics. Investigators determined that higher vancomy-
cin MIC and lower level of bactericidal activity correlated with prolonged
MRSA bacteremia. Vancomycin MIC of 2 mg/mL had an odds ratio of
14.7 (95% CI, 2.26–100; P ¼ .005) for failure of vancomycin to eradicate
MRSA. Reduction in log10 CFU/mL less than 2.5 had an odds ratio of
6.7 (95% CI, 1.03–43.5; P ¼ .047) for failure of vancomycin to eradicate
MRSA. This led the investigators to conclude that even with the increase
of the MIC to only 2 mg/mL, which is in the ‘‘susceptible’’ range, there
was an alarmingly low rate of clearing of bacteremia. Furthermore, bacteri-
cidal activity of vancomycin was predictive of treatment failure independent
of MIC. This study again underscores the need for better treatment in
MRSA infections with higher MICs to vancomycin and seriously challenges
the MIC breakpoints for intermediate susceptibility.Vancomycin
Vancomycin is a glycopeptide antibiotic that is given as an intravenous
infusion of 15 mg/kg twice daily in patients with normal renal function.
The drug exerts its effect via inhibition of the cross-linkage of d-alanine to
d-alanine in the cell wall of the bacteria, thus interfering with peptidoglycan
synthesis Its pharmacodynamic bactericidal activity is best described as
time-dependent killing, with area under the curve (AUC) and time above
the MIC being the best predictors of activity [14]. Vancomycin distributes
to most tissues well but penetration into the lung and cerebral spinal fluid
is poor. The drug is 100% renally excreted and regimens need to be adjusted
if renal impairment exists. Vancomycin is considered a ‘‘monitorable’’ drug
because the laboratories of most institutions can assess serum levels. While
vancomycin was initially associated with renal toxicity and ototoxicity, these
are now rare with the currently available formulation [15].
It has been known for a while that vancomycin’s activity against MSSA is
inferior to that of antistaphylococcal beta-lactam antibiotics. In a recent
prospective observational study comparing nafcillin to vancomycin for the
treatment of MSSA bacteremia, risk factors for relapse of S aureus bacter-
emia included valvular heart disease, cirrhosis of the liver, deep-seated infec-
tion (ie, endocarditis), and treatment with vancomycin [16]. Vancomycin
remained a risk factor for relapse on multivariate analysis with an odds ratio
of 6.5 (95% CI, 1.0–52.8; P!.048).
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pneumonia due to MRSA. However concern about suboptimal penetration
of the lung and about the clinical implications of potentially decreased drug
concentrations has led to interest in optimizing the dose of vancomycin by
targeting higher trough levels. The only study looking specifically at in-
creased trough concentrations and outcomes in pneumonia is a retrospective
cohort study done by Jeffres and colleagues [17]. This study examined 102
patients with MRSA health care–associated pneumonia (HCAP) over a
6.5-year period. Neither mean trough concentrations nor mean AUC values
differed significantly between the survivors and nonsurvivors. When the
groups were broken into increments of 5 mg/mL (5–10 mg/mL, 10–15 mg/
mL, 15–20 mg/mL, and O20 mg/mL), there was a trend toward decreased
mortality in the trough of the 15- to 20-mg/mL group, though, as compared
with other trough groups, it was not statistically significant. This led the in-
vestigators to conclude that there was no evidence for higher vancomycin
trough levels or AUC levels to predict survival. The trial demonstrated no
evidence for the value of increased trough levels. At the same time, however,
because the study may have been underpowered to detect a difference in out-
comes, it also did not prove the lack of correlation with trough level and
treatment outcomes. Its retrospective nature and the estimation of trough
levels by population kinetics models may also have weakened the validity
of the conclusions. While the utility of attaining higher vancomycin trough
levels in hospital-associated pneumonia (HAP), HCAP, and VAP is still un-
proven, the Infectious Diseases Society of America (IDSA)/American Tho-
racic Society (ATS) published guidelines for treatment of HAP, HCAP, and
VAP recommend that, if vancomycin is used, it should dosed to achieve
trough levels of 15 to 20 mg/mL [18].
Another attempt at improving outcomes with vancomycin has been to
administer vancomycin as a continuous infusion. However, in a prospective,
randomized study of 84 critically ill patients, efficacy and safety did not dif-
fer between those patients treated with continuous infusion and those with
standard intermittent vancomycin therapy [19].
The most common side effect of vancomycin is an infusion-related phe-
nomenon referred to as red-neck syndrome. Infusion of vancomycin triggers
histamine release via mast cell degranulation, and patients become flushed
and may become pruritic. The adverse effect can be attenuated by infusing
the drug over a longer period of time. However, despite all of the concerns
mentioned above, vancomycin continues to be commonly used in the treat-
ment of MRSA infections.Quinupristin-dalfopristin
New alternatives to vancomycin for the treatment of MRSA began to ap-
pear with the approval of quinupristin-dalfopristin in the late 1990s. Quinu-
pristin-dalfopristin inhibits protein synthesis at the 50S ribosomal subunit
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drug are the development of arthalgia andmyalgia during infusionof the drug.
Quinupristin-dalfopristin has been studied in the treatment of nosoco-
mial pneumonia [20]. The study reported that clinical cure was achieved
in 49 (56.3%) patients receiving quinupristin-dalfopristin and in 49
(58.3%) patients receiving vancomycin (absolute difference 2%; 95% CI,
16.8–12.8). The mortality rates were 25.3% in the quinupristin-dalfopristin
group and 21.6% vancomycin group (P ¼ .45). Based on the results of this
study, quinupristin-dalfopristin does not appear to have a primary role in
the management of MRSA pneumonia. Its high cost, increased risk of
side effects, multiple drug interactions, and equivocal results greatly dimin-
ish its utility in the treatment of serious MRSA infections.Linezolid
Linezolid is an oxazolidinone antibiotic with activity against a variety of
gram-positive organisms, including MRSA. It is considered bacteriostatic
against S aureus and exerts its effect by inhibiting bacterial protein synthesis
by binding to the 70S initiation complex. It is dosed at 600mg twice daily, and
both oral and intravenous formulations are available. It distributes well into
most tissues, including skin, fat, bone, lung, and cerebral spinal fluid [21]. It
does not require renal or hepatic adjustment in those with impaired organ
function. Caution should be used in patients taking concurrent selective sero-
tonin re-uptake inhibitors because mild inhibition of monoamine oxidase by
linezolid can cause serotonin syndrome to occur. Linezolid has also been re-
ported to be associated with increased risk of thrombocytopenia, though one
trial determined no difference as compared with treatment with vancomycin
when used for short courses of therapy [22]. In addition, linezolid therapy
rarely has been associated with the development of optic neuritis and periph-
eral neuropathy. The drug has not been well studied for long-term use (O28
days) and increased monitoring is warranted if therapy exceeds 28 days.
Linezolid has been studied head-to-head versus vancomycin for the treat-
ment of MRSA pneumonia. Two multicenter, randomized, double-blind
studies compared linezolid to vancomycin for nosocomial pneumonia
[23,24]. The subset of patients treated for MRSA pneumonia has been re-
examined in two retrospective subgroup analyses [25,26]. The total number
of patients treated in the two nosocomial pneumonia clinical trials was 1019
with a subgroup of 160 patients with MRSA pneumonia. Baseline character-
istics differed in a few important ways, though a statistical analysis was not
performed as to the significance of these imbalances. There were higher per-
centages of patients with cardiac comorbidities (24% linezolid versus 40%
vancomycin) and diabetes (17.3% linezolid versus 38.8% vancomycin) in
the vancomycin-treated group. Renal comorbidities were also different in
the two groups (13.3% linezolid versus 21.2% vancomycin), though patients
with serum creatinine greater than 229.8 mol/L (2.6 mg/dL) was similar (4%
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matched in terms of APACHE II score, age, and concomitant bacteremia.
The overall mortality rate was 20% for the linezolid group as compared
with 36.5% for the vancomycin group (P ¼ .03). The clinical cure rate
was 59% in the linezolid-treated group versus 35.5% in the vancomycin-
treated group (P!.01). The investigators concluded that linezolid is supe-
rior to vancomycin for the treatment of MRSA pneumonia. This conclusion
has been challenged because of the perceived suboptimal treatment in the
vancomycin-treated group, because of the imbalance in cardiac comorbid-
ities, and because this was a subgroup analysis. A study sponsored by Pfizer
(NCT00037050) is underway to resolve this issue.
The utility of linezolid in the treatment of bacteremia is limited to one ret-
rospective study of pooled results of five studies [27]. Of 144 patients with
infection due to S aureus, 53 had MRSA bacteremia. Clinical cure rate
for MRSA infections was 56% in patients treated with linezolid and 46%
in patients treated with vancomycin, (odds ratio 1.47; 95% CI, 0.5–4.34).
Survival was 74% in both treatment groups. Neither treatment was associ-
ated with increased rate of clinical cure or survival in the multivariate anal-
ysis. A recently completed, yet unpublished, trial (NCT00037050) compared
linezolid to either vancomycin or oxacillin-dicloxacillin for the treatment of
catheter-related bacteremia. Overall mortality was higher in the linezolid-
treated patients, leading the Food and Drug Administration to add a warn-
ing to linezolid packaging about the risk of mortality in linezolid-treated
catheter-related bloodstream infections.Daptomycin
Daptomycin is a cyclic lipopeptide antibioticwithactivity againstMRSA. It
exerts its effect by rapidly depolarizing the bacterial cell membrane via the for-
mation of potassium efflux channels. Pharmacodynamically, the drug is bacte-
ricidal and its killing effect is best predicted by concentration-to-MIC ratio. It
is dosed at 4mg/kg intravously every 24 hours in skin and skin-structure infec-
tions and at 6 mg/kg every 24 hours for S aureus bacteremia [28]. It is renally
excreted andmust be dose-adjusted in the setting of renal impairment. Dapto-
mycin has a limited volume of distribution. However, at standard doses, it can
achieve therapeutic levels in the blood and soft tissues. Treatment with dapto-
mycin may cause elevations in the creatine kinase and the development of my-
algia [28]. Patients should be monitored for symptoms of muscle pain and
creatine kinase should be monitored at baseline and weekly during therapy.
Daptomycin’s role in the critically ill patient is primarily in the treatment
of bacteremia. The drug should not be used to treat pneumonia because it
has been shown to be inferior to ceftriaxone in the treatment of community
acquired pneumonia in an unpublished study (NCT00538694). These infe-
rior results are likely because daptomycin penetrates the lung poorly and
binds to surfactant [29].
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to either daptomycin or standard treatment for the treatment of S aureus
bacteremia. Patients were excluded if pneumonia was present or estimated
creatinine clearance was less than 30 mL per minute. The standard therapy
treatment arm consisted of vancomycin for MRSA isolates and an antista-
phylococcal penicillin, such as oxacillin, for the MSSA isolates. Gentamicin
dosed 1 mg/kg intravenously three times daily was added to the treatment
regimen in all patients with standard treatment and in patients in the dapto-
mycin group with left-sided endocarditis for the first 4 days of therapy.
Treatment success was defined as absence of clinical failure, microbiological
failure, death, failure to obtain blood culture, receipt of potentially effective
study antibiotics, or premature discontinuation of the drug. Treatment suc-
cess occurred in 53 of 120 patients (44.2%) in the daptomycin group versus
48 of 115 patients (41.7%) in the standard therapy group (absolute diff-
erence of 2.4%; 95% CI, 10.2–15.1). In the subgroup of patients with
MRSA bacteremia, no statistically significant differences in success were ob-
served. As a result, daptomycin met the noninferiority criteria for treatment
of bacteremia. The two antibiotic regimens exhibited similar safety and tol-
erability with the exception of a statistically significant increased incidence
of renal failure in those in the standard treatment group. This was postu-
lated to be a result of the addition of gentamicin, a known nephrotoxic
agent, to this treatment group. Daptomycin has been associated with eleva-
tions of creatine kinase and, accordingly, this study showed a statistically
significant increased incidence of creatinine kinase elevations in daptomy-
cin-treated patients (6.7% versus 0.9% in the standard treatment group).
Of those patients with elevated levels, 4 had a level greater than 10 times
the upper limit of normal, and 3 discontinued treatment as a result. Lastly,
this trial demonstrated a tolerance or acquired resistance to both daptomy-
cin and vancomycin while on therapy. In the daptomycin group, 6 of 120
isolates became resistant to daptomycin while on therapy and led to subse-
quent treatment failure. In the vancomycin group, frank resistance did not
occur. However, in 4 of the 53 patients who received vancomycin for
MRSA, the MIC increased to 2 mg/mL from a baseline of 0.5 mg/mL or
1 mg/mL. These patients also failed treatment.Tigecycline
Tigecycline is the first agent in the class of antibiotics known as the glyclcy-
clines. It shares structural similarities to minocycline and can be thought of as
a broad-spectrum tetracycline antibiotic. It acts by inhibiting the 30S ribo-
somal subunit in a way unique to current tetracyclines. Therefore it is often ef-
fective against pathogens that demonstrate tetracycline resistance. It exerts
a bacteriostatic effect on a wide range of gram-positive and gram-negative
agents, including MRSA. It is considered to exhibit time-dependent killing
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a 100-mg intravenous loading dose and 50mg intravenously twice daily there-
after. It does not require dose adjustment in renal impairment, though severe
hepatic impairment (Child Pugh classification) requires a maintenance dose
adjustment to 25 mg twice daily. The drug is extensively distributed through-
out the body. The distribution is such that maximum steady-state concentra-
tions in serum are only 0.6 mg/mL [32]. Treatment of infections with
concurrent bacteremia due to S aureus is cautioned as MICs vary between
0.03 and 0.5 mg/mL [33]. The side effect profile of the drug is similar to that
of minocycline, with gastrointestinal intolerance being the most common
treatment-limiting adverse event.
The drug has been extensively studied in skin and skin-structure infec-
tions as well as in intra-abdominal infections [34,35]. In the studies of
intra-abdominal infections, MRSA was not identified as a significant path-
ogen, and the comparator drug imipenem has no activity against MRSA.
Therefore, the only clinically relevant data to this discussion is pertaining
to treatment of MRSA as presented in two double-blind phase 3 trials com-
paring tigecycline to a combination of vancomycin and aztreonam for the
treatment of skin and skin-structure infection [35]. Microbiological success,
defined as eradication of MRSA in 65 patients suitable for evaluation,
occurred in 78% of patients treated with tigecycline versus 75.8% of those
treated with the vancomycin-aztreonam regimen. These data come with
the caveat that extensive exclusion criteria were implemented to select out
severely ill patients. Patients with necrotizing fasciitis, neutropenia, or
‘‘any condition or medication that would impair the ability to eradicate
infections’’ were excluded. The last measure would exclude many severely
ill patients who frequently receive their care in intensive care units.
The drug has been used with limited success in gram-negative pneumonia
with multidrug-resistant pathogens and, until recently, data consisted only
in case reports and series [36,37]. A study by Maroko and colleagues [38]
was presented at the 47th Interscience Conference on Antimicrobial Agents
and Chemotherapy and compared tigecycline to imipenem as part of an
empiric treatment regimen for HAP. Vancomycin could be added to the pa-
tients receiving imipenem, and ceftazidime and amikacin could be added to
tigecycline for coverage of Pseudomonas aeruginosa. The mean APACHE II
score in the study population was 12.3, indicating a relatively less severe
patient population. Tigecycline treatment was associated with poorer cure
rates in the population that could be clinically evaluated. Cure rates for
the tigecycline group were 67.9% as compared with 78.2% cure rates for
the imipenem group, with an absolute difference of 10.4% (95%
CI, 17.8, –3.0). The safety of tigecycline was also less favorable with a dis-
continuation rate of 10.9% versus a discontinuation rate of 6.6% for imipe-
nem. The pharmacokinetics favor the delivery of drug to the lung. However,
in light of the recent data, tigecycline should be used with caution to treat
HAP, VAP, and HCAP. Therefore, until further studies examine
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treatment of MRSA in the critically ill patient. In less severe patients with
intra-abdominal infections or skin and skin-structure infections due to
MRSA, tigecycline can be used interchangeably with vancomycin, especially
if the extended spectrum of tigecycline is needed for polymicrobial etiology.Trimethoprim-sulfamethoxazole and clindamycin
Many strains of MRSA are susceptible to trimethoprim-sulfamethoxa-
zole. This drug exerts its effect by interfering with bacterial folic acid synthe-
sis. It has been studied in comparison with vancomycin in only one
randomized double-blind study on efficacy of treatment for S aureus infec-
tions in 101 intravenous drug users [32]. MRSA caused infections in 47% of
these patients. Vancomycin was shown to be superior in terms of treatment
and safety. Therefore, trimethoprim-sulfamethoxazole’s role in critical set-
tings is severely limited and treatment should be confined to less severe
infections, such as outpatient treatment of laboratory-proven trimethoprim-
sulfamethoxazole–susceptible MRSA infections.
Clindamycin is an agent that in some cases can be considered for treat-
ment of MRSA infections. It is a lincosamide antibiotic and acts on the
50S ribosome inhibiting bacterial protein synthesis. Clindamycin resistance
can be constitutive or inducible. Inducible resistance is determined in the
microbiology laboratory during routine susceptibility testing. MRSA iso-
lates with the clindamycin-susceptible phenotype are commonly identified
as community-acquired MRSA (CA-MRSA) [39]. CA-MRSA can be in-
volved in serious infections as it can be associated with production of the
Panton-Valentine leukocidin exotoxin. Clindamycin is thought to decrease
the production of this exotoxin through its effects on bacterial protein syn-
thesis. In the critical care setting, however, with more serious infections, it
should not be given as a sole agent. In the case of necrotizing-type infections
due to Panton-Valentine leukocidin–positive MRSA, it may be prudent to
add clindamycin to the regimen for the duration of treatment [40]. Beyond
this use, clindamycin has not been studied for the treatment of severe infec-
tions due to MRSA, nor compared with any MRSA-active drugs in the
setting of a serious MRSA infection.Summary
The treatment of MRSA in the critically ill patient is complicated. Data
for treatment of critically ill patients are often lacking due to the exclusion
of patients with high mortality risk in larger clinical trials. In the setting of
nosocomial pneumonia, the evidence-based critical care practitioner must
choose vancomycin or linezolid for treatment of MRSA. Tigecycline should
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be considered because it is sequestered in lung secretions. The choice of line-
zolid or vancomycin should take into account patient-specific factors, such
as allergies, organ function, concomitant medications, MIC for each agent
as applied to the pathogen in question, and susceptibility trends from the
local antibiogram. It is prudent to consider the use of linezolid, especially
in patients with MRSA isolates with elevated vancomycin MICs and in pa-
tients for whom limited lung penetration is a concern. If vancomycin is used,
it is unclear if higher trough concentrations aimed at 15 to 20 mg/mL are
necessary for efficacy, or will effectively treat the higher susceptible MIC
pathogens. Because vancomycin is well tolerated, many practitioners will
target higher troughs despite the absence of data supporting the decision.
A prospective trial of MRSA pneumonia patients is underway to investigate
the issue of vancomycin versus linezolid in greater detail. This trial will, it is
hoped, settle the controversy.
In the patient with bacteremia, the primary concern is the source of the bac-
teremia. In a patient with concurrent pneumonia, the options are again line-
zolid and vancomycin. In a patient with a skin or skin-structure infection or
intra-abdominal infection with a secondary bacteremia, there are more
options. Vancomycin can be used and is the standard by which other agents
are judged. Daptomycin is effective in treating primary bacteremia due to
MRSA as well as bacteremia secondary to skin and skin-structure
infections. Tigecycline can be considered in select instances as well, though
blood levels are likely not sufficient for treating a primary bacteremia. As
with pneumonia, treatment choice should bemade after careful consideration
of patient characteristics and local trends of antibiotic resistance.
In the event a patient presents with a severe CA-MRSA infection, the
same reasoning discussed previously applies. However, addition of an agent
with a mechanism of action related to decreasing protein synthesis, such as
linezolid or clindamycin, should be considered as part of the regimen to
attenuate potential toxin production. If clindamycin is used in the critically
ill patient, it should be in combination with another drug active against
MRSA, such as vancomycin, until the patient is stabilized and susceptibili-
ties are known.
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